Key Financial Data Of Group

Kringle Pharma,Inc. - Filing #7264672

Concept 2024-10-01 to
2025-03-31
As at
2025-03-31
2023-10-01 to
2024-09-30
As at
2024-09-30
2023-10-01 to
2024-03-31
As at
2024-03-31
Key financial data of group
Business results of group
Net sales
35,928,000 JPY
80,038,000 JPY
43,029,000 JPY
Ordinary profit (loss)
-511,740,000 JPY
-754,961,000 JPY
-365,471,000 JPY
Net assets
1,608,710,000 JPY
2,108,192,000 JPY
2,322,294,000 JPY
Total assets
2,290,108,000 JPY
2,757,113,000 JPY
2,912,050,000 JPY
Basic earnings (loss) per share
-75.15
-118.21
-60.21
Diluted earnings per share
Equity-to-asset ratio
0.692 xbrli:pure
0.758 xbrli:pure
0.793 xbrli:pure
Net cash provided by (used in) operating activities
-404,516,000 JPY
-661,166,000 JPY
-315,253,000 JPY
Net cash provided by (used in) investing activities
-155,129,000 JPY
-121,363,000 JPY
-121,363,000 JPY
Net cash provided by (used in) financing activities
1,047,000 JPY
838,233,000 JPY
668,409,000 JPY
Cash and cash equivalents
1,258,345,000 JPY
1,816,943,000 JPY
1,993,032,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.